MDM2 and p21(WAF1/CIP1), wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease

Journal of Pathology

Volumn 180, Issue 1, 1996, Pages 58-64

  Sánchez Beato, Margarita ^a   Piris, Miguel A ^a   Martínez Montero, Juan C ^a   García, Juan F ^a   Villuendas, Raquel ^a   García, Francisco J ^a   Orradre, Juan L ^a   Martínez, Pedro ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Hodgkins' disease; MDM2; Oncogenes; p21(WAF1 CIP1); p53; PCNA; Tumour suppressor genes

Indexed keywords

CYCLINE; PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; RNA; TUMOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REED STERNBERG CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; ENZYME IMMUNOASSAY; GENE EXPRESSION; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; GENE EXPRESSION; HODGKIN DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REED-STERNBERG CELLS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029662063     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199609)180:1<58::AID-PATH610>3.0.CO;2-W     Document Type: Article

References (45)

1. Levine, AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
2. Hollstein M, Sindransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
3. Piris MA, Pezzella F, Martinez-Montero JC, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994; 69: 337-341.
4. Gupta RK, Norton AJ, Lister TA, Bodmer JG. p53 protein expression in Reed-Sternberg cells of Hodgkins disease. Leukemia 1993; 2: 31-33.
5. Doussis IA, Pezzella F, Lane DP, Gatter KC, Mason DY. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am J Clin Pathol 1993; 99: 663-667.
6. Niedobitek G, Rowlands DC, Young LS, et al. Overexpression of p53 in Hodgkin's disease: lack of correlation with Epstein-Barr. J Pathol 1993; 16: 207-212.
7. Gupta RK, Patel K, Bodmer WF, Bodmer JG. Mutation of p53 in primary biopsy material and cell lines from Hodgkin's disease. Proc Natl Acad Sci USA 1993; 90: 2817-2821.
8. Trümper LH, Brady G, Bagg A, et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells, molecular heterogeneity of gene expression and p53 mutations. Blood 1994; 81: 3097-3115.
9. Xerry L, Parc P, Bouabdallah R, Camerlo J, Hassoun J. PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease. J Pathol 1995; 175: 189-194.
10. Hummel M, Ziemann K, Lammert H, Pileri S, Sabattini E, Stein H. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells N Engl J Med 1995; 333: 901-906.
11. Roth J, Daus H, Trümper L, Gause A, Salamon-Looijen M, Pfreundschuh M. Detection of immunoglobulin heavy-chain rearrangement at the single-cell level in malignant lymphomas: no rearrangement is found in Hodgkin and Reed-Sternberg cells. Int J Cancer 1994; 57: 799-804.
12. Küppers R, Rajewsky K, Zhao M, et al. Hodgkin's disease: Hodgkin and Reed-Sternberg picked from histological sections show clonal immunoglobulin rearrangements and appear to be derived from B-cells at various stages of development. Proc Natl Acad Sci USA 1994; 91: 10962-10966.
13. Barak Y, Juven T, Haffner R, Oren M. MDM2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461-468.
14. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild type p53 can mediate sequence specific transactivation of an internal promoter within the MDM2 gene. Oncogene 1993; 8: 3411-3416.
15. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
16. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
17. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Mature 1993; 362: 857-860.
18. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levin AJ. Identification and characterization of multiple mdm2 proteins and mdm2-p53 protein complexes. Oncogene 1993; 8: 2353/2360.
19. Haines DS, Landers JE, Engle LJ, George DL. Physical and functional interaction between wild type p53 and mdm2 proteins. Mol Cell Biol 1994; 14: 1171-1178.
20. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994; 91: 2684-2688.
21. Ladanyi M, Cha CH, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatis osteosarcoma. Cancer Res 1993; 53: 16-18.
22. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994; 86: 1297-1302.
23. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
24. Reifenberger G, Lui L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-2739.
25. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993; 53: 3226-3228.
26. Bueso-Ramos CE, Yang Y, Leon E, McCown P, Stass SA, Albitar M. The human MDM2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617-2623.
27. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 9: 3158-3165.
28. Martinez JC, Mateo MS, Sánchez-Beato M, et al. MDM2 expression in lymphoid cells and tissue. Comparative study with p53 expression. J Pathol 1995; 177: 27-34.
29. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-825.
30. Harper JW, Adami GY, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinase. Cell 1993; 75: 805-816.
31. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
32. DiGiusseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53 independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-888.
33. Villuendas R, Piris MA, Algara P, et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993; 82: 3151-3156.
34. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 1993; 143: 845-856.
35. Nakamura H, Said JW, Miller CW, Koeffler HP. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood 1993; 82: 920-926.
36. McKee PH, Hobbs C, Hall PA. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 1993; 23: 377-379.
37. Martinez JC, Piris MA, Sánchez-Beato M, et al. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. J Pathol 1993; 169:405-412.
38. Chomczynsky P, Sacchi N. Single-step method of RNA isolation by acidic guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
39. Tso JY, Sun X-H, Kao T-H, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acid Res 1985; 13: 2485-2502.
40. Villuendas R, Piris MA, Orradre JL, et al. p53 protein expression in lymphomas and reactive lymphoid tissue. J Puthol 1992; 166: 235-241.
41. Chilosi M, Doglioni C, Menestrina F, et al. Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood 1994; 84: 4295-4300.
42. Landers JE, Haines DS, Straus JF III, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumour cells. Oncogene 1994; 9: 2745-2749.
43. Gerdes J. Van Baarlen J, Pileri S, Schwarting R, Van Unnik JAM, Stein H. Tumor cell growth fraction in Hodgkin's disease. Am J Pathol 1987; 128: 390-393.
44. Mosner J, Deppert W. p53 and MDM2 are expressed independently during cellular proliferation. Oncogene 1994; 9: 3321-3328.
45. Macleod KF, Sherry N, Hannon G, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935-944.